MAMarta Amaral

Marta Amaral

*This is an algorithmically generated author record based on publicly available information.

Marta Amaral has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Zeitaufgelöst und markerfrei gemessene ligandeninduzierte Konformationsänderungen von HSP90 – hin zu einem Konformationsaktivitätsscreening für die Wirkstoffentwicklung

    by Jörn Güldenhaupt, Marta Amaral, Carsten Kötting, Jonas Schartner, Djordje Musil, Matthias Frech, Klaus Gerwert

    Während der frühen Medikamentenentwicklung ist die Untersuchung der Protein‐Liganden‐Wechselwirkungen von entscheidender Bedeutung. Die ATR‐FTIR‐Spektroskopie kann Protein‐Liganden‐Wechselwirkungen markerfrei mit hoher räumlicher und zeitlicher Auflösung detektieren. Wir haben das Hitzeschockprotein HSP90, einen wichtigen molekularen Angriffspunkt für Medikamente, auf einem ATR‐Kristall immobilisiert und mit unserem neuartigen Ansatz eine ligandeninduzierte Sekundärstrukturänderung untersucht. Zwei spezifische Bindungsmodi von 19 Inhibitoren wurden analysiert. Unterschiedliche Bindungsmodi können zu unterschiedlicher Wirksamkeit und Spezifität verschiedener Medikamente führen. Darüber hinaus wurden die kobs‐Werte der Dissoziation der Liganden ermittelt. Die Ergebnisse werden durch Röntgenkristallographie für die Strukturänderung und SPR‐Experimente für die Dissoziationskinetik validiert, wobei unsere Methode sämtliche Daten in einem einzigen und einfachen Experiment liefert.

  • Open Access

    Ligand‐Induced Conformational Changes in HSP90 Monitored Time Resolved and Label Free—Towards a Conformational Activity Screening for Drug Discovery

    by Jörn Güldenhaupt, Marta Amaral, Carsten Kötting, Jonas Schartner, Djordje Musil, Matthias Frech, Klaus Gerwert

    Investigation of protein–ligand interactions is crucial during early drug‐discovery processes. ATR‐FTIR spectroscopy can detect label‐free protein–ligand interactions with high spatiotemporal resolution. Here we immobilized, as an example, the heat shock protein HSP90 on an ATR crystal. This protein is an important molecular target for drugs against several diseases including cancer. With our novel approach we investigated a ligand‐induced secondary structural change. Two specific binding modes of 19 drug‐like compounds were analyzed. Different binding modes can lead to different efficacy and specificity of different drugs. In addition, the kobs values of ligand dissociation were obtained. The results were validated by X‐ray crystallography for the structural change and by SPR experiments for the dissociation kinetics, but our method yields all data in a single and simple experiment.


  • Open Access

    Estimation of Drug-Target Residence Times by τ-Random Acceleration Molecular Dynamics Simulations

    by Daria B. Kokh, Marta Amaral, Joerg Bomke, Ulrich Grädler, Djordje Musil, Hans-Peter Buchstaller, Matthias K. Dreyer, Matthias Frech, Maryse Lowinski, Francois Vallee, et al.

    Drug-target residence time (τ), one of the main determinants of drug efficacy, remains highly challenging to predict computationally and, therefore, is usually not considered in the early stages of drug design. Here, we present an efficient computational method, τ-random acceleration molecular dynamics (τRAMD), for the ranking of drug candidates by their residence time and obtaining insights into ligand-target dissociation mechanisms. We assessed τRAMD on a data set of 70 diverse drug-like ligands of the N-terminal domain of HSP90α, a pharmaceutically important target with a highly flexible binding site, obtaining computed relative residence times with an accuracy of about 2.3τ for 78% of the compounds and less than 2.0τ within congeneric series. Analysis of dissociation trajectories reveals features that affect ligand unbinding rates, including transient polar interactions and steric hindrance. These results suggest that τRAMD will be widely applicable as a computationally efficient aid to improving drug residence times during lead optimization.


  • Top Cited Papers
    Open Access

    Protein conformational flexibility modulates kinetics and thermodynamics of drug binding

    by M. Amaral, D. B. Kokh, J. Bomke, A. Wegener, H. P. Buchstaller, H. M. Eggenweiler, P. Matias, C. Sirrenberg, R. C. Wade, M. Frech

    Structure-based drug design has often been restricted by the rather static picture of protein–ligand complexes presented by crystal structures, despite the widely accepted importance of protein flexibility in biomolecular recognition. Here we report a detailed experimental and computational study of the drug target, human heat shock protein 90, to explore the contribution of protein dynamics to the binding thermodynamics and kinetics of drug-like compounds. We observe that their binding properties depend on whether the protein has a loop or a helical conformation in the binding site of the ligand-bound state. Compounds bound to the helical conformation display slow association and dissociation rates, high-affinity and high cellular efficacy, and predominantly entropically driven binding. An important entropic contribution comes from the greater flexibility of the helical relative to the loop conformation in the ligand-bound state. This unusual mechanism suggests increasing target flexibility in the bound state by ligand design as a new strategy for drug discovery.


  • The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease

    by Marta Amaral, Tiago F. Outeiro, Nigel S. Scrutton, Flaviano Giorgini

    Metabolites of the kynurenine pathway (KP), which arise from the degradation of tryptophan, have been studied in detail for over a century and garnered the interest of the neuroscience community in the late 1970s and early 1980s with work uncovering the neuromodulatory potential of this pathway. Much research in the following decades has found that perturbations in the levels of KP metabolites likely contribute to the pathogenesis of several neurodegenerative diseases. More recently, it has become apparent that targeting KP enzymes, in particular kynurenine 3-monooxygenase (KMO), may hold substantial therapeutic potential for these disorders. Here we provide an overview of the KP, the neuroactive properties of KP metabolites and their role in neurodegeneration. We also discuss KMO as a therapeutic target for these disorders, and our recent resolution of the crystallographic structure of KMO, which will permit the development of new and improved KMO inhibitors which may ultimately expedite clinical application of these compounds.


  • Open Access

    Structural basis of kynurenine 3-monooxygenase inhibition

    by Marta Amaral, Colin Levy, Derren J. Heyes, Pierre Lafite, Tiago F. Outeiro, Flaviano Giorgini, David Leys, Nigel S. Scrutton

    Inhibition of kynurenine 3-monooxygenase (KMO) leads to amelioration of Huntington’s-disease-relevant phenotypes in yeast, fruitfly and mouse models; here the crystal structures of free and inhibitor-bound yeast KMO are presented, which could aid the development of targeted therapies for human neurodegenerative diseases. The kynurenine pathway is the major route of tryptophan degradation in mammals, and some metabolites generated by tryptophan degradation have an important role in neurodegenerative disorders. Inhibition of the kynurenine 3-monooxygenase (KMO) enzyme leads to the amelioration of Huntington's-disease-relevant phenotypes in various animal models. This paper presents the structure of KMO in the free form and in complex with an inhibitor. This study will provide the basis for the development of inhibitors for possible therapeutic use in neurodegenerative diseases. Inhibition of kynurenine 3-monooxygenase (KMO), an enzyme in the eukaryotic tryptophan catabolic pathway (that is, kynurenine pathway), leads to amelioration of Huntington’s-disease-relevant phenotypes in yeast, fruitfly and mouse models1,2,3,4,5, as well as in a mouse model of Alzheimer’s disease3. KMO is a flavin adenine dinucleotide (FAD)-dependent monooxygenase and is located in the outer mitochondrial membrane where it converts l-kynurenine to 3-hydroxykynurenine. Perturbations in the levels of kynurenine pathway metabolites have been linked to the pathogenesis of a spectrum of brain disorders6, as well as cancer7,8 and several peripheral inflammatory conditions9. Despite the importance of KMO as a target for neurodegenerative disease, the molecular basis of KMO inhibition by available lead compounds has remained unknown. Here we report the first crystal structure of Saccharomyces cerevisiae KMO, in the free form and in complex with the tight-binding inhibitor UPF 648. UPF 648 binds close to the FAD cofactor and perturbs the local active-site structure, preventing productive binding of the substrate l-kynurenine. Functional assays and targeted mutagenesis reveal that the active-site architecture and UPF 648 binding are essentially identical in human KMO, validating the yeast KMO–UPF 648 structure as a template for structure-based drug design. This will inform the search for new KMO inhibitors that are able to cross the blood–brain barrier in targeted therapies against neurodegenerative diseases such as Huntington’s, Alzheimer’s and Parkinson’s diseases.